Prescription Drug Reform
Expert articles and analysis related to prescription drug reform.
AI Summary â Last 24 Hours
Synthesis:
In the past 24 hours, CMS issued a final rule updating Medicare Advantage and Part D payment policies, drawing scrutiny from observers who note a gap between President Trumpâs stated stance on insurers and the administrationâs regulatory actions, particularly regarding drug pricing and benefit designâa dynamic with direct implications for ACOs and population health initiatives Arnold Ventures statement / STAT News on policy tensions. In parallel, CMS
Related Articles
STAT+: Maryland state affordability board sets its first price cap for a medicine
The board will now oversee a process to lower the cost of the type 2 diabetes medicine Jardiance by January 2027.
CMS Proposes Reforms to Speed Patient Access to Drugs
CMS Proposes Reforms to Speed Patient Access to Drugs  HCI Innovation Group
Oral Wegovy sounds easy, but the reality is more complicated [PODCAST]
Subscribe to The Podcast by KevinMD. Watch on YouTube. Catch up on old episodes! Is the new oral Wegovy pill a breakthrough or a risk most patients never hear about? Shiv K. Goel, an internal medicine...
Exparelâs Proven Clinical and Economic Value Underpins Buy Rating and $38 Price Target on Pacira BioSciences
Exparelâs Proven Clinical and Economic Value Underpins Buy Rating and $38 Price Target on Pacira BioSciences  TipRanks
STAT+: FDA pushes drugmakers to report missing clinical trial results
FDA officials said an internal analysis found results were not submitted for nearly 30% of studies âhighly likelyâ to fall under mandatory reporting requirements.
The Latest In Health And Finances: From GLP-1 Drugs To Goldman Sachs
The Latest In Health And Finances: From GLP-1 Drugs To Goldman Sachs  Dallas Express
STAT+: Pharmalittle: Weâre reading about a pancreatic cancer pill, FDA rejecting a Replimune drug again, and more
Metastatic pancreatic cancer patients who received a targeted pill from Revolution Medicines lived nearly twice as long as patients who got chemotherapy
STAT+: Allogene Therapeuticsâ CAR-T treatment eliminates residual cancer cells in B-cell lymphoma patients
The new data bolster Allogeneâs efforts to develop a new, easily administered cell therapy that could delay or prevent cancer recurrence.
Pharmacy closures threaten our entire public health system
We turned pharmacies into the backbone of public health during coronavirus disease 2019 (COVID-19). Then we went back to paying them like retail stores. The result is what I think of as the pharmacy p...
STAT+: Spyre Therapeutics IBD drug shows promise in early trial
The inflammatory bowel disease therapy succeeded in its first major testing, setting up a competition with several large drugmakers.